Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Real-time Evaluation and Continuous Observation of Vital Signs for Enhanced Recovery: a Study for the Early Identification of Complications in the Surgical Ward Following Surgery in Patients Not Eligible for Intensive Care Admission. (RECOVER)

22. Juli 2026 aktualisiert von: Valentina Bellini, Azienda Ospedaliero-Universitaria di Parma

Real-time Evaluation and Continuous Observation of Vital Signs for Enhanced Recovery

This study aims to evaluate whether continuous vital sign monitoring with wearable devices can help detect postoperative complications in surgical ward earlier than standard hospital monitoring. In particular, the goal of this observational study is to evaluate if the wireless wearable devices Portrait Mobile (GE Healthcare) can detect early signs of complications after major urologic surgery in adults who are not eligible for intensive care unit admission. The main questions it aims to answer are:

  • Can continuous monitoring of vital signs (heart rate, breathing rate, blood oxygen) detect health problems earlier than standard nurse checks in the urology ward?
  • How many times do participants' vital signs change in ways that suggest a complication is developing during the first days after surgery?
  • Does the vital sign trend and/or the deviation from patients' baseline suggest a complication is developing during the first days after surgery?
  • Does continuous monitoring help healthcare providers intervene before patients become critically ill thus reducing complications burden or severity and reducing unplanned intensive care admission? Participants in the intervention cohort will wear a wireless patch-like device on their chest that continuously tracks their heart rate, breathing rate, and blood oxygen levels. The device sends this information to hospital staff through a secure wireless connection while participants recover in the regular urology ward after surgery. Participants in the intervention cohort will wear the device for 3 days after surgery or until they leave the hospital. Healthcare providers will receive alerts if vital signs change in ways that suggest a complication may be developing. This may help providers treat problems earlier and prevent patients from becoming critically ill. All participants will also receive standard post-surgical care, including regular nurse checks of vital signs.

Studienübersicht

Detaillierte Beschreibung

The RECOVER study evaluates the use of continuous wearable monitoring in surgical ward for the early detection of postoperative complications in patients recovering after major surgery. The study begins with the evaluation of urologic surgery. It focuses on whether continuous measurement of vital signs in the surgical ward can identify clinical deterioration and postoperative complications earlier than routine postoperative surveillance alone: postoperative complications are often preceded by changes in vital signs and may develop during the first days after surgery, when patients are usually monitored intermittently in the ward. Continuous wireless monitoring is intended to provide earlier recognition of respiratory and hemodynamic deterioration while patients recover outside the operating room and outside intensive care.

The main objective is to assess whether continuous monitoring of vital signs can detect early signs of medical or surgical postoperative complications after moderate-to-high complexity urologic surgery performed under general anesthesia. The protocol is particularly focused on identifying episodes of desaturation, tachypnea, hemodynamic instability, and persistent deviation of vital signs from patient's baseline values during the postoperative period.

Patient enrollment takes place in the Urology ward before the scheduled operation. During the preoperative anesthesiology evaluation, the anesthesiologist provides study information and asks the patient to participate by signing informed consent and personal data processing forms. This enrollment process is maintained in both patient pathways described in the protocol.

For patients managed with continuous monitoring, the wearable system is applied on the evening before surgery so that baseline vital sign values can be collected under resting conditions. Monitoring is interrupted before transfer to the operating room and restarted after the patient returns from surgery to the ward. The patient then wears the system for at least 72 hours after surgery, and the device does not replace standard postoperative monitoring.

The wearable platform used in the protocol is the Portrait Mobile® system by GE HealthCare. It continuously records respiratory rate, oxygen saturation, and heart rate, while blood pressure and EKG continues to be measured intermittently according to usual ward practice in order to maintain the non-intensive care settings and the actual patient-nurse ratio. Data are transmitted through the hospital Wi-Fi network to a dedicated monitoring infrastructure, where alarms can be visualized on the ward monitoring station.

Alarm thresholds are predefined by the investigator using values derived from the National Early Warning System Score. These thresholds include respiratory rate below 11 or above 21 breaths per minute, oxygen saturation below 95%, and heart rate below 50 or above 91 beats per minute. In addition to threshold-based events, the protocol evaluates persistent deviation from baseline, defined as a change greater than 20% for at least 24 hours, in order to capture clinically meaningful trends rather than isolated abnormal values.

When an alarm is generated, ward nursing staff are asked to determine whether the alert is appropriate or represents a false positive. They also record whether the patient is at rest or moving at the time of the alert, allowing the investigators to assess device performance under real clinical conditions. Subsequent clinical actions, including review by the ward physician, on-call physician activation, or request for anesthesiology consultation, are reconstructed from nursing handover and the clinical chart.

For patients managed with usual postoperative surveillance alone, enrollment still occurs during the preoperative anesthesiology assessment and clinical data are collected after informed consent is obtained. These patients receive standard ward monitoring without wearable continuous monitoring, and their postoperative course is documented for comparison of clinical events and outcomes.

The primary endpoints are the number of desaturation events, tachypnea events, and hemodynamic instability events. Secondary endpoints include false positive rate, number of physician alerts, number of requests for intensive care consultation, unplanned intensive care admission directly from the operating area, transfer to intensive care during postoperative ward stay, postoperative complications, re-surgery, correlation between parameter trends and outcomes, hospital length of stay, barriers to rehabilitation, patient satisfaction, and integration of the system with the hospital IT infrastructure.

All complications will be recorded in the case report form and graded according to the Clavien-Dindo classification. Collected data include baseline patient characteristics, average preoperative vital sign values, diagnosis, type of surgery, intraoperative data, continuous monitoring data, postoperative clinical course, pain, functional recovery, total hospital stay, ICU stay, and patient satisfaction with the monitoring system.

The system is not expected to expose patients to additional risk and does not interfere with the usual diagnostic and therapeutic pathway. Wireless wearable monitoring should not negatively affect mobilization, rehabilitation, or functional recovery, which is relevant because preservation of postoperative recovery is one of the practical concerns addressed by the study.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

150

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • Parma
      • Parma, Parma, Italien, 43126
        • Rekrutierung
        • 2^ Anestesia, Rianimazione, Terapia Intensiva - Azienda Ospedaliero Universitaria di Parma
        • Kontakt:
        • Kontakt:
        • Hauptermittler:
          • Valentina Bellini
        • Unterermittler:
          • Matteo Panizzi

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Adult patients undergoing to major urological surgery performed under general anesthesia and without a planned intensive care unit admission.

Beschreibung

Inclusion Criteria:

  • Ability to give informed consent and consent to the processing of personal data by signing the relevant forms;
  • Aged over 18 years old
  • Medium-to-high complexity urological surgery without the need for post-operative monitoring in the Intensive Care Unit
  • Surgery performed under general anaesthesia
  • Discharge to the ward is scheduled upon leaving the operating theatre

Exclusion Criteria:

  • Refusal or inability to consent to participation
  • Patients under 18 years old
  • Planned admission to Post-Operative Intensive Care Unit after the surgery
  • Unplanned admission to the Post-Operative Intensive Care Unit at the end of the surgery
  • Anaesthetic technique other than general anaesthesia.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Standard intermittent monitoring (Control)
100 patients receiving standard intermittent nurse vital sign check
Wearable device continuous vital sign monitoring (Intervention)
50 patients receiving wearable device continuous vital sign monitoring with Portrait Mobile (GE Healthcare). Parameters monitored: Heart Rate, SpO2, Respiratory Rate.
The wearable system is applied on the evening before surgery so that baseline vital sign values can be collected under resting conditions. Monitoring is interrupted before transfer to the operating room and restarted after the patient returns from surgery to the ward. The patient then wears the system for at least 72 hours after surgery. Respiratory rate, oxygen saturation, and heart rate are continuously collected, while blood pressure and EKG continues to be measured intermittently according to usual ward practice in order to maintain the non-intensive care settings and the actual patient-nurse ratio. Alarm thresholds are predefined by the investigator using values derived from NEWS and alarms calibrated over baseline parameters.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of event of desaturation
Zeitfenster: 72 hours after the surgery
An 'event' among the primary outcomes will be those used by the National Early Warning System Score (NEWS: Respiratory rate <11 and >21 breaths/min; SpO₂ <95%; Heart rate <50 bpm and >91 bpm)
72 hours after the surgery
Number of event of tachypnoea or bradypnoea
Zeitfenster: 72 hours after the surgery
An 'event' among the primary outcomes will be those used by the National Early Warning System Score (NEWS: Respiratory rate <11 and >21 breaths/min; SpO₂ <95%; Heart rate <50 bpm and >91 bpm)
72 hours after the surgery
Number of event of haemodinamic instability
Zeitfenster: 72 hours after the surgery
An 'event' among the primary outcomes will be those used by the National Early Warning System Score (NEWS: Respiratory rate <11 and >21 breaths/min; SpO₂ <95%; Heart rate <50 bpm and >91 bpm)
72 hours after the surgery

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
False-positive rate
Zeitfenster: 72 hours after the surgery
Number of alarms triggered without a real Event
72 hours after the surgery
Number of on-call doctor call-outs
Zeitfenster: 72 hours after the surgery
Nurse activation of the medical staff of the surgery ward
72 hours after the surgery
Number of requests for Anesthesia consultation
Zeitfenster: 72 hours after surgery
Activation of Hospital medical emergency team
72 hours after surgery
Unscheduled direct admission to the Intensive Care Unit from the operating theatre and unplanned transfer to the Intensive Care Unit during the post-operative period (from the surgical ward)
Zeitfenster: 72 hours after surgery
After Anesthesiological evaluation and activation of Hospital medical emergency team
72 hours after surgery
Occurrence of post-surgical complications (any type) or reoperation
Zeitfenster: 72 hours after surgery or patients discharge
Any type of complication and their severity (Clavien Dindo score) that occur during the intervention period
72 hours after surgery or patients discharge
Correlation between parameters trend, including persistent deviation from pre-operative values, and patient outcome or length of hospital stay.
Zeitfenster: Untill patient discharge from hospital
To investigate the incidence of complication and/or prolonged LOS if the patient experience a progressive postoperative deviation from baseline vital parameters.
Untill patient discharge from hospital
Barriers to patient rehabilitation and patients satisfaction
Zeitfenster: 72 hours after surgery or discharge
Investigate whether the wearable device hinders patient rehabilitation, expressed as the percentage of patients reporting a reduced capacity for postoperative early mobilization or rehabilitation, and patients global satisfaction through a questionnaire.
72 hours after surgery or discharge

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

10. Februar 2026

Primärer Abschluss (Geschätzt)

1. Februar 2027

Studienabschluss (Geschätzt)

1. Februar 2027

Studienanmeldedaten

Zuerst eingereicht

15. Juli 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. Juli 2026

Zuerst gepostet (Tatsächlich)

28. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

28. Juli 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. Juli 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Raw IPD that underlie results

IPD-Sharing-Zeitrahmen

At the end of enrollment and data collection

IPD-Sharing-Zugriffskriterien

Upon request to the Principal Investigator

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren